# Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/anlotinib-for-previously-treated-advanced-or-metastatic-esophageal-squamous-cell/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jing Huang,Juxiang Xiao,Wentao Fang,Ping Lu,Qingxia Fan,Yongqian Shu,Jifeng Feng,Shu Zhang,Yi Ba,Yang Zhao,Ying Liu,Chunmei Bai,Yuxian Bai,Yong Tang,Yan Song,Jie He |
| Citations | 117 |
| DOI | 10.1002/cam4.3771 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://doi.org/10.1002/cam4.3771 |
| OpenAlex ID | https://openalex.org/W3131270109 |
| PMID | 33586360 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Yan Song](https://scholariq.org/researchers/yan-song/)

## Paper journal

- [Cancer Medicine](https://scholariq.org/journals/cancer-medicine/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.